Evidence map›Paper›PMID 35305226›Full record

ArticleMolecular biology reports2022

Promotion of NR1I3-mediated liver growth is accompanied by STAT3 activation.

Mark E Mazin, Andrei A Yarushkin, Yuliya A Pustylnyak, Elena A Prokopyeva, Vladimir O Pustylnyak

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mark E MazinNovosibirsk State University, Pirogova Street, 1, Novosibirsk, Russia, 630090.
Andrei A YarushkinFederal Research Center of Fundamental and Translational Medicine, Timakova Street, 2/12, Novosibirsk, Russia, 630117.
Yuliya A PustylnyakNovosibirsk State University, Pirogova Street, 1, Novosibirsk, Russia, 630090.
Elena A ProkopyevaNovosibirsk State University, Pirogova Street, 1, Novosibirsk, Russia, 630090.
Vladimir O PustylnyakNovosibirsk State University, Pirogova Street, 1, Novosibirsk, Russia, 630090. pustylnyak@post.nsu.ru.ORCID http://orcid.org/0000-0003-0547-5534
Novosibirsk State University · RUFederal Research Center of Fundamental and Translational Medicine · RU

Funding

Russian Science Foundation 18-15-00021
6 · The paper itself

Abstract

backgroundThe constitutive androstane receptor (CAR, NR1I3)-mediated mechanisms regulating hepatocyte proliferation and growth of the liver did not yet experience complete elucidation. We investigated whether STAT3 could be activated in vivo by NR1I3 signaling in mouse liver. METHODS AND

resultsUsing Western blot analysis, immunofluorescence assays and real-time PCR we established the state of STAT3 activation when it comes to the mouse liver subsequent to treatment ofNR1I3 agonist,1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP). STAT3 nuclear relocation and hepatocyte growth were both induced by NR1I3-mediated phosphorylation of STAT3. Moreover, the NR1I3-STAT3 signaling pathway's proliferation impact was facilitated, partly, by cMyc and Cyclin D1 upregulation.

conclusionsThis work's evidence demonstrates that NR1I3-pushed STAT3 activation contributes to TCPOBOP-induced liver growth and hepatocyte proliferation, at least in part, through its molecular targets cMyc and CyclinD1.

Indexed as

LiverReceptors, Cytoplasmic and NuclearAnimalsCell ProliferationHepatocytesMiceMice, Inbred C57BLSignal TransductionReceptors, Cytoplasmic and NuclearCARHepatocyte proliferationLiverLiver hyperplasiaSTAT3

Identifiers

PMID35305226
OpenAlexW4221128548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.